Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
= 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, low TMB does not preclude generation of effective antigen responses, nor does high TMB guarantee response to ICT (130-132).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
In the citing paper
“For example, it was shown that anti-CTLA4 therapy can induce effective neoantigen-specific T-cell responses in patients with prostate cancer, even in the background of low TMB (131).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
In the citing paper
“Multiple studies have reported that tumors identified as having”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [131]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 2×
“The median number of nonsynonymous somatic mutations was 76 in the cohort of 27 patients (table S5), which was much lower compared to melanoma and NSCLC (median number of nonsynonymous somatic mutations about 200) (3, 22), but was consistent for prostate cancer (1, 23).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Interferon-–responsive gene signature and tumor-infiltrating lymphocytes are associated with favorable responses to ipilimumab The presence of tumor-infiltrating lymphocytes and interferon- (IFN-)–responsive gene signatures have been shown to be predictive of responses to ICB (7, 8, 16, 17).”
Background
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationIdentification of neoantigens for individualized therapeutic cancer vaccines
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Sahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 534
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Zeng, D., Wu, J., Luo, H., Li, Y., Xiao, J., Peng, J., Ye, Z., Zhou, R., Yu, Y., Wang, G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002467 · Cited by 236
Hummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Tang, Z., Pilié, P. G., Geng, C., Manyam, G. C., Yang, G., Park, S., Wang, D., Peng, S., Wu, C., Peng, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1010 · Cited by 135
Wong, H. Y., Sheng, Q., Hesterberg, A. B., Croessmann, S., Rios, B. L., Giri, K. R., Jackson, J., Miranda, A. X., Watkins, E., Schaffer, K. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33780-1 · Cited by 142
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 137
Gromeier, M., Brown, M. C., Zhang, G., Lin, X., Chen, Y., Wei, Z., Beaubier, N. T., Yan, H., He, Y., Desjardins, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20469-6 · Cited by 139
Weiner, A. B., Vidotto, T., Liu, Y., Mendes, A. A. D. A., Salles, D. C., Faisal, F. A., Murali, S., McFarlane, M., Imada, E. L., Zhao, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21245-w · Cited by 116
3D Printing Scaffold Vaccine for Antitumor Immunity
Zhang, Y., Xu, J., Fei, Z., Dai, H., Fan, Q., Yang, Q., Chen, Y., Wang, B., & Wang, C. (2021) · Advanced Materials · doi:10.1002/adma.202106768 · Cited by 104
Sensitive identification of neoantigens and cognate TCRs in human solid tumors
Arnaud, M., Chiffelle, J., Genolet, R., Rodrigo, B. N., Perez, M. A. S., Huber, F., Magnin, M., Nguyen‐Ngoc, T., Guillaume, P., Baumgaertner, P., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01072-6 · Cited by 115
Immune-Checkpoint Blockade Enhances225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
Czernin, J., Current, K., Mona, C. E., Nyiranshuti, L., Hikmat, F., Radu, C. G., & Lückerath, K. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.246041 · Cited by 93
Burbach, B. J., O’Flanagan, S. D., Shao, Q., Young, K. M., Slaughter, J. R., Rollins, M. R., Street, T. J. L., Granger, V., Beura, L. K., Azarin, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24132-6 · Cited by 108
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 106
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Self-citationLi, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 105
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
Immune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 87
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
Sridaran, D., Bradshaw, E., DeSelm, C. J., Pachynski, R. K., Mahajan, K. N., & Mahajan, N. P. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101199 · Cited by 94
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 83
Rennier, K. R., Krug, E., Virdi, G., Shin, W. J., & Pachynski, R. K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4245 · Cited by 74
Advances in and prospects of immunotherapy for prostate cancer
Liu, D., Wang, L., & Guo, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217155 · Cited by 84
The evolving role of immune cells in prostate cancer
Wang, C., Zhang, Y., & Gao, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.027 · Cited by 81
Current and emerging therapies for neuroendocrine prostate cancer
Alabi, B. R., Liu, S., & Stoyanova, T. I. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108255 · Cited by 76
Fizazi, K. S., Retz, M. M., Petrylak, D. P., Goh, J. C. H., Perez‐Gracia, J. L., Lacombe, L., Zschäbitz, S., Burotto, M., Mahammedi, H., Gravis, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004761 · Cited by 67
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 67
Advancing nanotechnology for neoantigen-based cancer theranostics
Zou, J., Zhang, Y. X., Pan, Y., Mao, Z., & Chen, X. S. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00162h · Cited by 63
Subudhi, S. K., Siddiqui, B. A., Aparicio, A. M., Yadav, S. S., Basu, S., Chen, H., Jindal, S., Tidwell, R. S. S., Varma, A., Logothetis, C. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002919 · Cited by 67
Sridaran, D., Chouhan, S., Mahajan, K. N., Renganathan, A., Weimholt, C., Bhagwat, S., Reimers, M. A., Kim, E. H., Thakur, M. K., Saeed, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34724-5 · Cited by 61
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
Aktar, N., Yueting, C., Abbas, M., Zafar, H., Paiva‐Santos, A. C., Zhang, Q., Chen, T., Ahmed, M., Raza, F., & Zhou, X. (2022) · Journal of Oncology · doi:10.1155/2022/8901326 · Cited by 62
Deng, P., Wang, Z., Chen, J., Liu, S., Yao, X., Liu, S., Liu, L., Yu, Z., Huang, Y., Xiong, Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159628 · Cited by 50
Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer
Nguyen, T., Sridaran, D., Chouhan, S., Weimholt, C., Wilson, A., Luo, J. R., Li, T., Koomen, J. M., Fang, B., Putluri, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38887-7 · Cited by 41
Emerging Immunotherapy Approaches for Treating Prostate Cancer
Meng, L., Yang, Y., Mortazavi, A., & Zhang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814347 · Cited by 44
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
Brown, L. C., Halabi, S., Somarelli, J. A., Humeniuk, M. S., Wu, Y. S., Oyekunle, T. O., Howard, L. E., Huang, J., Anand, M., Davies, C., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00524-7 · Cited by 41
Progression in immunotherapy for advanced prostate cancer
Liang, H., Liu, Y., Guo, J., Dou, M., Zhang, X., Hu, L., & Chen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1126752 · Cited by 42
Zhu, Y., Zhao, Y., Wen, J., Liu, S., Huang, T., Hatial, I., Peng, X., Janabi, H. A., Huang, G., Mittlesteadt, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade4656 · Cited by 40
Luo, C., Chen, J., & Chen, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106709 · Cited by 35
McGrail, D. J., Pilie, P. G., Dai, H., Lam, T., Liang, Y., Voorwerk, L., Kok, M., Zhang, X. H.-F., Rosen, J. M., Heimberger, A. B., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6201 · Cited by 36
Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., & Nakatsura, T. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291558 · Cited by 36
The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma
Lamhamedi-Cherradi, S.-E., Maitituoheti, M., Menegaz, B. A., Krishnan, S., Vetter, A. M., Camacho, P. E., Wu, C.-C., Beird, H. C., Porter, R. W., Ingram, D. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30710-z · Cited by 37
Rahmy, S., Mishra, S. J., Murphy, S. P., Blagg, B. S. J., & Lü, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005045 · Cited by 34
Sherry, A. D., Siddiqui, B. A., Haymaker, C., Fellman, B. M., Medina-Rosales, M. N., Bathala, T. K., Wang, S., Liu, S., Seo, A., Hara, K., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.006 · Cited by 38
Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer
Wang, L., Pan, S., Zhu, B., Yu, Z., & Wang, W. (2021) · BMC Urology · doi:10.1186/s12894-021-00795-7 · Cited by 35
Immunotherapy in prostate cancer: new horizon of hurdles and hopes
Tsaur, I., Brandt, M. P., Juengel, E., Manceau, C., & Ploussard, G. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03497-1 · Cited by 31
Mutational characteristics of bone metastasis of lung cancer
Huang, X., Shi, X., Huang, D., Li, B., Lin, N., Pan, W., Yan, X., Li, H., Hao, Q., & Ye, Z. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1595 · Cited by 27
Labadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 37
Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
Amsberg, G. V., Alsdorf, W. H., Karagiannis, P., Coym, A., Kaune, M., Werner, S., Graefen, M., Bokemeyer, C., Bergmann, L., & Dyshlovoy, S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052569 · Cited by 27
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
López‐Campos, F., Gajate, P., Romero-Laorden, N., Zafra, J., Juan, M., Polo, S. H., Conde-Moreno, A. J., & Couñago, F. (2022) · Biomedicines · doi:10.3390/biomedicines10030537 · Cited by 25
Noori, M., Azizi, S., Mahjoubfar, A., Varaki, F. A., Fayyaz, F., Mousavian, A.-H., Bashash, D., Parizi, M. K., & Kasaeian, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181051 · Cited by 28
The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
Wei, J., Feng, J., Weng, Y., Xu, Z., Jin, Y., Wang, P., Cui, X., Ruan, P., Luo, R., Li, N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706910 · Cited by 21
Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity
Huang, Y., Zhong, W.-Q., Yang, X., Shan, J., Zhou, L., Li, Z., Guo, Y.-Q., Zhang, K., Du, T., Zhang, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58740-3 · Cited by 26
Immunotherapy for prostate cancer: Requirements for a successful regime transfer
Jeong, S., & Kwak, C. H. (2022) · Korean journal of urology · doi:10.4111/icu.20210369 · Cited by 21
Targeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 20
Faghfuri, E. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0054 · Cited by 20
CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer
Li, W., Guo, F., Zeng, R., Liang, H., Wang, Y., Xiong, W., Wu, H., Yang, C., & Jin, X. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3704 · Cited by 20
Graff, J. N., Stein, M. N., Surana, R., Rabadi, L. S. A., Liu, E. V., Fong, L. H., Bailey, S., Latour, E. J., Newby, T. A., Moran, A. E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01381 · Cited by 21
Xu, Y., Zhang, Z., Zhang, P., An, Z., & Sun, C. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220413092507 · Cited by 18
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 19
Adaptive Immunity in Genitourinary Cancers
Koti, M., Bivalacqua, T. J., Black, P. C., Cathomen, T., Galsky, M. D., Gulley, J. L., Ingersoll, M. A., Kamat, A. M., Kassouf, W., Siemens, D. R., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.03.002 · Cited by 20
Chemerin triggers migration of a CD8 T cell subset with natural killer cell functions
Ballet, R., LaJevic, M. D., Mullin, N. E. H., Roach, R., Brulois, K., Huang, Y., Saeed, M. A., Dang, H. X., Pachynski, R. K., Wilson, E. B., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.015 · Cited by 20
Mustafa, A. R., Miyasato, D. L., & Wehrenberg-Klee, E. P. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.10.033 · Cited by 19
AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression
Wang, Q., Wu, Y., Long, Y., Li, R., Shi, Y., Zheng, Y., Chen, X., Li, X., Zhou, Y., Huang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62381-x · Cited by 32
A novel integrated approach to predicting cancer immunotherapy efficacy
Luo, R., Chyr, J., Wen, J., Wang, Y., Zhao, W., & Zhou, X. (2022) · Oncogene · doi:10.1038/s41388-023-02670-1 · Cited by 16
Progress in cancer vaccines enabled by nanotechnology
Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 24
Moustaki, A., Crawford, J. C., Alli, S., Fan, Y., Boi, S. K., Zamora, A. E., McDonald, N., Wu, G., Nakitandwe, J., Newman, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abf6136 · Cited by 17
Flickinger, J. C., Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A. M., Waldman, S. A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00483-z · Cited by 17
Niknafs, N., Najjar, M., Dennehy, C., Stouras, I., & Anagnostou, V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0824 · Cited by 22
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics
Das, S., Ganguly, S. C., Bera, S., & Kundu, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02763-1 · Cited by 17
A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response
Zou, C., He, Q., Feng, Y., Chen, M., & Zhang, D. (2022) · NAR Cancer · doi:10.1093/narcan/zcac010 · Cited by 18
Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view
Arab, F. L., Hoseinzadeh, A., Hafezi, F., Mohammadi, F. S., Zeynali, F., Tehran, M. H., & Rostami, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112171 · Cited by 19
Szabó, P. M., Pant, S., Ely, S. A., Desai, K., Anguiano, E., Wang, L., Edwards, R. H., Green, G., & Zhang, N. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.06.002 · Cited by 16
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Huang, F., Li, K., Shevach, J. W., & Wang, Q. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.04.004 · Cited by 29
Calvo, E., Doger, B., Carles, J., Peer, A., Sarid, D. L., Eigl, B. J., Avadhani, A. N., Yao, D. F., Lin, V. W., Wu, S., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyae313 · Cited by 14
Park, M. N., Choi, J., Fahim, M. M. H., Asevedo, E. A., Nurkolis, F., Ribeiro, R. I. M. D. A., Kang, H. N., Kang, S., Syahputra, R. A., & Kim, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1504618 · Cited by 16
Chen, L., Zheng, Y., Jiang, C., Yang, C., Zhang, L., & Liang, C. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009634 · Cited by 13
Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
Wu, J. D. (2021) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2021037614 · Cited by 13
Cui, X., Yu, H., Yao, J., Li, J., Li, Z., & Jiang, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-10424-7 · Cited by 13
Han, S., Shi, T., Liao, Y., Chen, D., Yang, F., Wang, M., Ma, J., Li, H., Xu, Y., Zhu, T., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03827-4 · Cited by 16
Chen, Z., Wang, Y., Fong, W. P., Hu, M.-T., Liang, J., Wang, L., & Li, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107890 · Cited by 10
Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities
Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 12
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy
Velaga, R., Koo, K. M., & Mainwaring, P. N. (2022) · Immunotherapy · doi:10.2217/imt-2022-0081 · Cited by 13
Utilization of cancer immunotherapy in sub-Saharan Africa
Olatunji, E., Patel, S., Graef, K. M., Joseph, A. O., Lasebikan, N. N., Mallum, A. A., Chigbo, C. O., Jaffee, E. M., & Ngwa, W. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1266514 · Cited by 12
Recent developments in neoantigen-based cancer vaccines
Hodge, K. G., Supabphol, S., Kumar, P., Poomipak, W., & Pisitkun, T. (2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-120520-0841 · Cited by 15
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., Mishima, Y., Hiranuka, K., Watanabe, N., Yamada, T., Nakamura, N., & Nakatsura, T. (2022) · Cancer Science · doi:10.1111/cas.15291 · Cited by 10
Burton, E. M., Amaria, R. N., Cascone, T., Chalabi, M., Gross, N. D., Mittendorf, E. A., Scolyer, R. A., Sharma, P., & Ascierto, P. A. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03472-x · Cited by 9
Zhao, F., Zeng, J., Chen, C., Zhao, X., Zhang, T., THOMAS, G. V., Sears, R. C., Alumkal, J. J., Moran, A. E., Mills, G. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.18.629070 · Cited by 13
Yan, X., Dong, H., Gao, L., Liu, M., & Wang, C. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214339 · Cited by 9
de Graaf, J. F., Pesic, T., Spitzer, F. S., Oosterhuis, K., Camps, M. G. M., Zoutendijk, I., Teunisse, B., Zhu, W., Arakelian, T., Zondag, G. C. M., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200835 · Cited by 14
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
Siddiqui, B. A., Subudhi, S. K., & Sharma, P. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100613 · Cited by 10
Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers
Ruel, L., Li, Z., Gaudreault, N., Henry, C., Armero, V. E. S., Boudreau, D. K., Zhang, T., Landi, M. T., Labbé, C., Couture, C. Y., et al. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-0630 · Cited by 13
CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives
Calabrò, M. L., Ettari, R., Chio, C. D., Luca, F. D., Previti, S., & Zappalà, M. (2025) · Biomedicines · doi:10.3390/biomedicines13102545 · Cited by 11
Metadata
- Authors
- Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., Pisters, L. L., Troncoso, P., Tidwell, R. S., Thall, P., Wu, C.-J., Zhang, J., Logothetis, C. L., Futreal, A., Allison, J. P., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Corresponding author
- Allison, James P.
- Sharma, Padmanee
- ORCID
- Subudhi, Sumit K.
- Vence, Luis
- Zhao, Hao
- Blando, Jorge
- Yadav, Shalini S.
- Xiong, Qing
- Reuben, Alexandre
- Aparicio, Ana
- Corn, Paul G.
- Chapin, Brian F.
- Pisters, Louis L.
- Troncoso, Patricia
- Tidwell, Rebecca Slack
- Thall, Peter
- Wu, Chang-Jiun
- Zhang, Jianhua
- Logothetis, Christopher L.
- Futreal, Andrew
- Allison, James P.
- Sharma, Padmanee
- Venue
- Science Translational Medicine
- Published
- 2020-04
- Volume
- 12
- Issue
- 537
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3014592760
- Cited by
- 158
- References
- 36
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 17 · 2023: 21 · 2022: 34 · 2021: 36 · 2020: 16
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, prostate cancer, neoantigens, immune checkpoint blockade, tumor mutational burden, CD8+ T cells, IFN-gamma response, antigen-specific T cell responses, metastatic prostate cancer, survival, immune correlates
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Humans, Male, Prostatic Neoplasms, Biomarkers, Tumor, Cohort Studies, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.